ReviewLife (Basel, Switzerland)2024
Exosome-Derived miRNAs in Liquid Biopsy for Lung Cancer.
Review in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Lung tumour secretome and extracellular vesicles: mechanisms, biomarkers, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Article
- Review
- A noninvasive urinary microRNA-based assay for early detection of lung cancer and its potential application to prognosis and recurrence monitoring: a case-control study.NPJ precision oncology · 2026Article
- Liquid biopsy biomarkers for accurate detection of malignant pulmonary nodules: a meta-analytic approach.Discover oncology · 2026Article
- MicroRNAs in Prostate Cancer Liquid Biopsies: Early Detection, Prognosis, and Treatment Monitoring.Cells · 2026Review
- Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment.Translational lung cancer research · 2025Review
- Exosome-Derived microRNAs as Liquid-Biopsy Biomarkers in Laryngeal Squamous Cell Carcinoma: A Narrative Review and Evidence Map.Biomedicines · 2025Review
- Deep Learning-Driven Multimodal Integration of miRNA and Radiomic for Lung Cancer Diagnosis.Biosensors · 2025Review
- Exosomes in early lung cancer diagnostics: the current state of progress made and prospects.Frontiers in cell and developmental biology · 2025Review
- Advances in the role of extracellular vesicles in circulating microRNA biomarker discovery for lung cancer.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Exosome-derived microRNAs (miRNAs) are potential biomarkers for lung cancer detection and monitoring through liquid biopsy. These small, non-coding RNA molecules are found within exosomes, which are extracellular vesicles released from cells. Their stability in biofluids, such as blood, positions them as candidates for minimally invasive diagnostics. Multiple studies have shown that lung cancer patients exhibit distinct miRNA profiles compared to healthy individuals. This finding suggests that exosome-derived miRNAs could serve as valuable biomarkers for diagnosis, prognosis, and evaluating therapeutic responses. This review summarizes recent research on exosome-derived miRNAs in liquid biopsies, including blood, pleural effusion, and pleural lavage, as biomarkers for lung cancer, focusing on publications from the last five years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.